Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Leases: 2019-2023

Historic Current Leases for Spyre Therapeutics (SYRE) over the last 4 years, with Jun 2023 value amounting to $4.3 million.

  • Spyre Therapeutics' Current Leases rose 807.97% to $4.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $4.3 million, marking a year-over-year increase of 807.97%. This contributed to the annual value of $625,000 for FY2022, which is 43.35% up from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Current Leases is $4.3 million, which was up 612.34% from $608,000 recorded in Q1 2023.
  • Spyre Therapeutics' 5-year Current Leases high stood at $4.3 million for Q2 2023, and its period low was $228,000 during Q2 2020.
  • Its 3-year average for Current Leases is $866,300, with a median of $467,000 in 2022.
  • Its Current Leases has fluctuated over the past 5 years, first crashed by 30.49% in 2020, then skyrocketed by 807.97% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Current Leases (Quarterly) stood at $351,000 in 2019, then fell by 9.12% to $319,000 in 2020, then skyrocketed by 36.68% to $436,000 in 2021, then soared by 43.35% to $625,000 in 2022, then surged by 807.97% to $4.3 million in 2023.
  • Its last three reported values are $4.3 million in Q2 2023, $608,000 for Q1 2023, and $625,000 during Q4 2022.